Metagenomi (NASDAQ:MGX) & Esperion Therapeutics (NASDAQ:ESPR) Head-To-Head Analysis

Esperion Therapeutics (NASDAQ:ESPR) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Profitability

This table compares Esperion Therapeutics and Metagenomi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	-3.66%	N/A	-3.93%
Metagenomi	-348.54%	-47.14%	-33.82%

Volatility and Risk

Esperion Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Esperion Therapeutics and Metagenomi, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1	2	3	1	2.57
Metagenomi	1	0	3	1	2.80

Esperion Therapeutics currently has a consensus price target of $5.54, suggesting a potential upside of 78.14%. Metagenomi has a consensus price target of $10.00, suggesting a potential upside of 619.42%. Given Metagenomi’s stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Esperion Therapeutics.

Earnings and Valuation

This table compares Esperion Therapeutics and Metagenomi”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14 million	1.99	-$22.68 million	($0.17)	-18.29
Metagenomi	$25.21 million	2.08	-$87.87 million	($2.37)	-0.59

Esperion Therapeutics has higher revenue and earnings than Metagenomi. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

47.4% of Esperion Therapeutics shares are held by institutional investors. 1.7% of Esperion Therapeutics shares are held by company insiders. Comparatively, 17.8% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Esperion Therapeutics beats Metagenomi on 8 of the 13 factors compared between the two stocks.

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.